A medical diagnostic flowchart titled 'CN Stage 0 Evaluation Algorithm Part II', outlining the clinical pathway for suspected Charcot Neuroarthropathy (CN). The algorithm begins with the clinical presentation of a 'Red Hot Swollen Foot'. The primary diagnostic step involves ordering weight-bearing (WB) radiographs, shown as an anteroposterior X-ray image of the foot. Simultaneously, the clinician should consider and exclude other differential diagnoses. If the radiograph is positive (+) for CN signs, or if radiographs are negative and a subsequent MRI (shown as a sagittal T1-weighted image) is positive, the patient is transitioned to a non-weight-bearing (NWB) status and referred to a foot specialist. If both imaging modalities are negative (-) for diagnostic features of CN, the algorithm concludes that Charcot foot is unlikely. This educational resource is designed for podiatrists and orthopedic specialists to assist in the early identification and management of Charcot Neuroarthropathy Stage 0 to prevent permanent structural foot deformity.

Summary : This flowchart presents a diagnostic algorithm for idiopathic pulmonary fibrosis (IPF), detailing the stepwise evaluation of patients suspected of having IPF, including assessment of potential causes, imaging patterns, multidisciplinary discussion, and biopsy options. flowchart: # Nodes : • Patient suspected of having IPF (rectangle) • Potential cause/associated condition (rectangle) • Confirmation of specific diagnosis (including with HRCT) (rectangle) • Chest HRCT pattern (rounded rectangle) • UIP or probable UIP* (rectangle) • Indeterminate for UIP or alternate diagnosis (rectangle) • MDD (multidisciplinary discussion) (rounded rectangle, appears twice) • BAL† ± TBLC‡ (rectangle) • SLB‡ (rectangle) • IPF (rectangle) • Alternative diagnosis (rectangle) # Connectors : • Patient suspected of having IPF → Potential cause/associated condition (down arrow) • Potential cause/associated condition → Confirmation of specific diagnosis (right arrow, labeled "Yes") • Confirmation of specific diagnosis → Alternative diagnosis (down arrow, labeled "Yes") • Potential cause/associated condition → Chest HRCT pattern (down arrow, labeled "No") • Chest HRCT pattern → UIP or probable UIP* (left branch) • Chest HRCT pattern → Indeterminate for UIP or alternate diagnosis (right branch) • UIP or probable UIP* → MDD (down arrow) • Indeterminate for UIP or alternate diagnosis → MDD (down arrow) • MDD → BAL† ± TBLC‡ (left branch) • MDD → SLB‡ (right branch) • BAL† ± TBLC‡ → MDD (dashed arrow to right, indicating possible subsequent step) • SLB‡ → MDD (down arrow) • MDD (second instance) → IPF (left arrow) • MDD (second instance) → Alternative diagnosis (right arrow) # Layout : • The flowchart is organized top-to-bottom, with initial patient assessment at the top. • Branching occurs based on presence of potential cause/associated condition. • Imaging (HRCT) and diagnostic pattern assessment are central. • Multidisciplinary discussion (MDD) is a key decision node, leading to biopsy options. • Final outcomes are IPF or alternative diagnosis at the bottom. # Analysis : • The algorithm emphasizes exclusion of known causes before considering IPF. • HRCT imaging pattern is pivotal in guiding further workup. • Multidisciplinary discussion is required for diagnosis, especially in cases with probable UIP pattern. • Biopsy options (BAL, TBLC, SLB) are considered for indeterminate cases, with iterative discussion. • The process is designed to minimize unnecessary invasive procedures and ensure accurate diagnosis.

This flowchart delineates a diagnostic and management strategy for cardiovascular (CV) complications in patients undergoing CAR-T cell therapy. The clinical algorithm is organized into three sequential phases: Baseline CV Evaluation, Infusion Monitoring, and Post-Infusion Surveillance. The baseline phase involves CV risk factor assessment, ECG, baseline cardiac biomarkers (e.g., troponin, NT-proBNP), and transthoracic echocardiography (TTE) for patients with pre-existing heart disease. The infusion phase focuses on vital sign assessment, telemetry, monitoring for Cytokine Release Syndrome (CRS), and symptom-driven biomarker assessment. Post-infusion surveillance is risk-stratified based on American Society for Transplantation and Cellular Therapy (ASTCT) CRS grading. High-grade CRS (ASTCT ≥2) triggers tocilizumab administration, repeat cardiac biomarkers, and TTE for Left Ventricular Ejection Fraction (LVEF) assessment. Low-grade CRS requires continued ECG and vital signs monitoring. This infographic serves as a clinical guideline for oncologists and cardiologists to manage cardiotoxicity and systemic inflammatory responses during advanced immunotherapy.